Nexobrid is expected to drive growth in 2025, with Macy Arthro contributing modestly. Macy's 20% growth is sustained by strong indicators. Early Arthro cases show promise for new adoption and increased customer utilization, with significant impact expected in 2025.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing